INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 21, 2023...
Day: February 21, 2023
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
EDMONTON, Alberta, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage...
Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder
Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe...
Hatch Medical Retained By EndoBar Solutions To Sell Embolotherapy System, Lamina™
SANTA ROSA BEACH, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C....
Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations
CE Marking for the company’s portable MRI system with AI-powered imaging software demonstrates that the system complies with safety and...
Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced TherapyMALVERN, Pa.,...
Yield10 Bioscience Announces Key Advancements in the Development of Herbicide Tolerant Camelina Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market
-Second field trial confirms Camelina tolerance to over-the-top herbicide application -Greenhouse studies support proof-of-concept for stacked herbicide traits in Camelina...
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from...
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee...
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ETSOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) --...
ICU Medical to Present at the Raymond James 44th Annual Institutional Investors Conference
SAN CLEMENTE, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and...
Science 37 to Report Fourth Quarter 2022 Financial Results on March 6, 2023
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today...
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity...
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Predictive Oncology launches ACE program to partner with academic and research institutions to advance their drug discovery initiatives
First round of applications due March 31, 2023EAGAN, Minn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today...
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023...
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein...